## **Core Concept**
The question tests understanding of DPP-IV inhibitors, a class of oral hypoglycemic agents used in the treatment of type 2 diabetes mellitus. DPP-IV inhibitors work by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which is involved in the inactivation of incretin hormones. This leads to an increase in insulin secretion and a decrease in glucagon levels.

## **Why the Correct Answer is Right**
The correct answer, , is a DPP-IV inhibitor that is primarily excreted via the liver and bile, making it suitable for use in patients with renal failure. Unlike some other DPP-IV inhibitors that are primarily excreted by the kidneys, does not require dose adjustment in patients with renal impairment, making it a safer choice for this population.

## **Why Each Wrong Option is Incorrect**
* **Option A:** is primarily excreted by the kidneys, and its use in renal failure may require dose adjustments, making it less ideal compared to .
* **Option B:** also undergoes significant renal excretion and may not be the best choice for patients with renal failure without dose adjustment.
* **Option D:** is another DPP-IV inhibitor that is mainly excreted by the kidneys, which could be a concern in patients with renal impairment.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that is particularly useful in patients with type 2 diabetes and renal impairment due to its liver excretion pathway, which reduces the risk of accumulation and hypoglycemia. This makes a preferred option in the management of diabetes in patients with kidney disease.

## **Correct Answer:** .